Gale Lab

Drug Development and Vaccines

 

 

 

Anti-viral Discovery

The Gale Lab is partnering with Kineta, Inc. to develop targeted therapeutics to activate innate antiviral defenses in virus infected patients.

The Gale Lab is working at the forefront of Hepatitis C therapy through efforts to improve the standard of care, interferon treatement, and through studies aimed at developing agonists of the RIG-I Pathway.

 

 

Gale Lab
 
Kineta, Inc.
 
     
 

UNIVERSITY OF WASHINGTON